Recently, it has been reported that Japan’s Kobayashi Pharmaceutical Company released an investigation report by external experts regarding health supplements containing beni kōji. The report indicates that although the production factory was aware of penicillin mold adhering to the beni kōji fermentation tanks, it neglected to take action.
The report states that during the inquiry and investigation of personnel related to the factory producing beni kōji raw materials, someone mentioned, “When we informed the quality control personnel about the penicillin mold adhering to the beni kōji fermentation tanks, we were told that it was possible for penicillin to mix in to some extent.”
Furthermore, the report criticizes the leadership capabilities of Kobayashi Pharmaceutical’s chairman Kazumasa Kobayashi and president Akihiro Kobayashi, stating that they “failed to make the necessary decisions and instructions to prioritize consumer safety.” On the morning of the 23rd, Kobayashi Pharmaceutical held an emergency board meeting, during which Kazumasa Kobayashi and Akihiro Kobayashi resigned.
The company stated that the decision was made “to clarify executive responsibility” over the issue involving its beni kōji fermented rice products.
In March, Kobayashi Pharmaceutical recalled five of its products after receiving reports of kidney problems from customers. The investigation began in January after a doctor alerted the company to reported health issues. A hotline was also established for customers seeking advice. Affected individuals reported symptoms such as changes in urine color, limb swelling, and fatigue.
The company later discovered a potentially toxic acid produced by mould at one of its factories. In a separate statement, the company’s board of directors expressed their condolences to the families of those who died and apologized to customers and business partners.
Satoshi Yamane, the head of sustainability policy, will assume the role of president. Akihiro Kobayashi, who has expressed a desire to take responsibility for any harm caused, will remain with the company to manage compensation arrangements.
According to reports, Kobayashi Pharmaceutical’s website shows that the company has a history spanning over 130 years. It focuses on product development and is primarily engaged in the research, production, and sales of pharmaceuticals, medical devices, daily necessities, and food products. Its products are sold not only in Japan but also in the United States, the United Kingdom, Southeast Asia, and other parts of the world. Currently, Kobayashi Pharmaceutical has approximately 155 brands and over 1,000 SKUs, including cosmetics like Hifmid moisturizing cream and moisturizing lotion.
Financial reports indicate that in the 2023 fiscal year, Kobayashi Pharmaceutical’s operating revenue was 173.5 billion yen, representing a 4.3% year-on-year increase. However, operating profit was 25.78 billion yen, a 3.3% year-on-year decrease. Prior to this, Kobayashi Pharmaceutical had maintained profit growth for 25 consecutive fiscal years.
